MicroRNAs and Long Non-coding RNAs in Genetic Diseases

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Non-coding RNAs, including microRNAs and long non-coding RNAs, play crucial roles in gene expression regulation.
• Dysregulation of these RNAs is implicated in the pathogenesis of various human diseases, particularly rare genetic disorders.
• The therapeutic potential of targeting non-coding RNAs is an area of growing research interest.

Purpose of the Study:

• To highlight the significance of microRNAs and long non-coding RNAs in rare genetic diseases.
• To discuss their potential as therapeutic targets for personalized medicine and orphan drug development.
• To review the current landscape and future prospects of non-coding RNA-based interventions for rare genetic conditions.

Main Methods:

• Literature review and synthesis of existing research on non-coding RNAs in rare genetic diseases.
• Analysis of regulatory frameworks for orphan medicinal products (EMA and FDA).
• Identification of specific rare genetic diseases where non-coding RNA analysis is a promising strategy.

Main Results:

• MicroRNAs and long non-coding RNAs are established regulators of gene expression and disease onset.
• Targeting these molecules presents a viable strategy for developing personalized therapies for rare genetic diseases.
• Diseases such as Duchenne muscular dystrophy, cystic fibrosis, Rett syndrome, and β-thalassemia are examples where non-coding RNA analysis shows promise.
• Existing regulations facilitate the development and approval of orphan medicinal products.

Conclusions:

• Non-coding RNA-targeting approaches are expected to significantly advance molecular diagnosis and therapy for rare genetic diseases.
• The established regulatory pathways for orphan drugs can accelerate the translation of these findings into clinical practice.
• Continued research into microRNAs and long non-coding RNAs holds substantial promise for treating rare genetic conditions.